CureVac reports Q1 revenue EUR 0.9M vs. EUR 12.4M last year

Operating loss amounted to EUR 54.7M for the first quarter of 2025, representing a decrease of EUR 18.6M from EUR 73.3M for the same period in 2024. Net financial result for the first quarter of 2025 amounted to EUR 3M, representing a decrease of EUR 0.4M from EUR 3.4M for the same period in 2024. “We entered 2025 with a strong momentum and robust balance sheet, driven by progress across our oncology and infectious disease programs, as well as successful execution of our strategic realignment,” said Alexander Zehnder, CEO. “With the FDA’s clearance of the IND for our lung cancer program and our glioblastoma study fully enrolled, we are steadily advancing an oncology pipeline that addresses high-unmet-need tumors. At the same time, we believe the European Patent Office’s recent rulings upholding two of our patents in amended form confirm the strength of our mRNA intellectual property estate. Backed by EUR 438M in cash, we are well positioned to unlock multiple pipeline catalysts later this year and continue to expand and execute on our next generation mRNA portfolio.”